Glaukos Corporation (GKOS), an ophthalmic medical technology and pharmaceutical company, on Tuesday reported a rise in preliminary sales for the fourth-quarter and full year.
In addition, the company has reaffirmed its full-year 2024 revenue outlook.
For the fourth-quarter, the company posted preliminary sales of over $81 million, compared with $71.227 million reported for the same period last year.
On average, 12 analysts polled by Thomson Reuters expect the firm to record revenue of $76.66 million, for the quarter.
For the full year, Glaukos recorded preliminary sales of over $313 million, higher than $282.862 million a year ago. Analysts, on average, project the company to post sales of $309.02 million, for the year.
For the twelve-month period, the company still expects to register sales of $350 million to $360 million, in line with analysts' estimate of $352.71 million.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.